Lilly's (LLY) Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

Eli Lilly's Omvoh emerging as the first IL-23p19 to show durable disease clearance in ulcerative colitis over four years is a significant milestone for both the drug and the company.

Newsquawk StaffPublished On the live feed at 10 more headlines followed before this page went public
Newsquawk headlinesUTC

Ferrari (RACE IM) Q1 2026 (EUR): EPS 2.33 (exp. 2.31), Revenue 1.85bln (exp. 1.83bln), EBITDA 722mln (exp. 710mln). Affirms FY26 guidance.

KKR & Co Inc (KKR) Q1 2026 (USD): EPS 1.39 (exp. 1.26), Revenue 4.32bln (may not compare to exp. 2.18bln); boosts buyback programme by USD 500mln and lifts dividend by 5%

Lilly's (LLY) Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

Marathon Petroleum (MPC) Q1 2026 (USD): adj. EPS 1.65 (exp. 0.74), Revenue 34.6bln (exp. 33.42bln)

EU Energy Commissioner comments on global energy crisis, stating it could be the worst ever faced

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This breakthrough may enhance Lilly's competitive position in the inflammatory bowel disease market, attracting interest from investors concerned about the pipeline's potential and the stock's future performance.

Related headlines

The whole workspace, free to try.

Try it free